Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dennis Patterson

Optometrist Sherman, TX Doctor of Optometry

NPI 1356357164 CMS profile 885287

4180 Town Ctr, Sherman, TX 75092

Open in the dashboard

General payments

$6,160

90 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dennis Patterson of Sherman, TX is reported in the CMS Open Payments database as having received $6,160 across 90 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $680 8
2024 General $705 8
2023 General $932 14
2022 General $980 13
2021 General $1,011 14
2020 General $722 13
2019 General $1,130 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dennis Patterson
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Dennis Patterson were reported at $680. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Dennis Patterson Optometrist median Middle half National median
2019 $1,130 $159 $67–$371 $163
2020 $722 $72 $29–$165 $114
2021 $1,011 $125 $46–$292 $132
2022 $980 $162 $66–$374 $149
2023 $932 $177 $72–$406 $160
2024 $705 $188 $77–$427 $164
2025 $680 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $2,274 30 payments
  2. Johnson & Johnson Vision Care, Inc. $1,592 24 payments
  3. Bausch & Lomb, a division of Bausch Health US, LLC $1,015 20 payments
  4. Bausch & Lomb Americas Inc. $603 8 payments
  5. Abbott Laboratories $228 1 payment
  6. RxSight Inc $146 1 payment
  7. New World Medical,Inc. $139 1 payment
  8. Ocular Therapeutix, Inc. $98 1 payment
  9. Eyevance Pharmaceuticals LLC $26 2 payments
  10. Astellas Pharma US Inc $25 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,160 90 payments
Products named General payments · program years 2019–2025
  1. Acuvue $1,249 19 payments
  2. Precision 1 $882 12 payments
  3. INFUSE $752 11 payments
  4. ULTRA $662 15 payments
  5. BIOTRUE ONE DAY $489 11 payments
  6. DAILIES $445 8 payments
  7. TOTAL30 $341 5 payments
  8. Precision7 $260 2 payments
  9. PROCLAIM $228 1 payment
  10. RXSIGHT CONTACT LENS $146 1 payment
  11. Other $1,710 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

290

Median for Optometry: 120

Drug cost

$4,864

Median for Optometry: $8,864

Branded share of claims

9%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 11 $2,655
Latanoprost Generic 179 $1,190
Brimonidine Tartrate Generic 56 $664
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 15 $190
Timolol Maleate Generic 29 $165

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$84,628

Medicare's payments for the services billed

Medicare patients

632

Average age 77

Services billed

1,359

395 women, 237 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 33%
Diabetes 28%
Atrial fibrillation 20%
Chronic kidney disease 20%
COPD 18%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

90 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record